Pfizer Inc (PFE)
Buenos Aires Exchange · Argentina · prices in ARS · close of 23 Oct 2026
Key indicators
| Last close | ARS 12,380.00 |
|---|---|
| 52-week range | 8,050.00 – 12,520.00 |
| Return, 1 month / 3 months | +9.6% / +24.8% |
| Return, 1 year / 3 years | +29.0% / −16.3% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 23.2% |
| Worst drawdown (1 year) | -14.1% |
| Average daily value traded | 271.24M ARS |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Pfizer is a pharmaceutical company that researches, develops and makes medicines and vaccines for patients around the world. Its products cover areas such as cancer care, immunology, heart and metabolic conditions, and infectious disease, and it supplies hospitals, clinics, pharmacies and health systems. The company is based in New York City in the United States and operates research, manufacturing and commercial sites in many countries, serving both healthcare professionals and governments.
The shares are listed on the Buenos Aires Exchange in Argentina under the code PFE, and the price on this page is in Argentine pesos (ARS). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Pfizer Inc (PFE) trades on the Buenos Aires Exchange in Argentina. It last closed at ARS 12,380.00 on 23 October 2026.
Its price-based Market X-Ray is 78 out of 100 (a strong price profile), ranking 11 of 154 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 29.0% and over the last three months it rose 24.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Buenos Aires Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 82 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.3% | ||
| From 52-week high | -0.5% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 24.8% | ||
| 6-month return | 26.5% | ||
| 12-month return, skipping the last month | 17.7% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.1% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 271.24M ARS | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.7% |
|---|---|
| 1 month | +9.6% |
| 3 months | +24.8% |
| 6 months | +26.5% |
| 1 year | +29.0% |
| 3 years | −16.3% |
| 5 years | +185.8% |
Signals
| 50-day / 200-day average | 11,334.80 / 10,205.92 |
|---|---|
| Golden / death cross (60 days) | Golden, 51 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 261.17 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Nov 2019 | USD 0.1800 |
| 1 Aug 2019 | USD 0.1800 |
| 9 May 2019 | USD 0.1800 |
| 31 Jan 2019 | USD 0.1800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Buenos Aires Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.